FDA
-
-
-
-
-
-
-
AEON Biopharma regains NYSE American listing compliance
-
-
-
-
-
-
-
AEON Biopharma Sets Annual Shareholder Meeting
-
-
-
-
-
-
-
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
-
-
-
-
-
-
-
AEON Biopharma signs debt exchange deal with Daewoong
-
-
-
-
-
-
-
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
AEON Biopharma Announces CEO Transition
-
-
-
-
-
-
-
AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering
-
329,906 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

